IGF-I/IGF-1 Antibody [Biotin]

• Reactivity: Mu
• Applications: WB, ELISA(Det)
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Biotin
• Concentration: LYOPH

IGF-I/IGF-1 Antibody [Biotin] Summary

• Immunogen: E. coli-derived recombinant mouse IGF-I/IGF-1
  Gly33-Ala102
  Accession # Q8CAR0
• Specificity: Detects mouse IGF-I/IGF-1 in ELISAs and Western blots. In sandwich immunoassays, less than 0.5% cross-reactivity with recombinant human IGF-I/IGF-1 is observed and less than 0.1% cross-reactivity with recombinant mouse IGF-II/IGF-2 is observed.
• Source: N/A
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Gene: IGF1
• Purity Statement: Antigen Affinity-purified

Applications/Dilutions

• Dilutions:
  • ELISA Capture (Matched Antibody Pair) 2-8 ug/mL
  • ELISA Detection (Matched Antibody Pair) 0.1-0.4 ug/mL
  • ELISA Standard (Matched Pair)
  • Western Blot 0.1 ug/mL
• Application Notes: ELISA Capture: Mouse IGF-I Antibody (Catalog # MAB791)
  ELISA Detection: Mouse IGF-I Biotinylated Antibody (Catalog # BAF791)
  Standard: Recombinant Mouse IGF-I (Catalog # 791-MG)
• Readout System:
  • Streptavidin Native Protein NBP2-29367
  • Streptavidin Native Protein NBP2-29370
  • Streptavidin Native Protein NBP2-29371

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Reconstitute at 0.2 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for IGF-I/IGF-1 Antibody [Biotin]

• IBP1
• IGF1
• IGF-1
• IGF1A
• IGFI
• IGF-I
• IGF-IA
• IGF-IB
• insulin-like growth factor 1 (somatomedin C)
• insulin-like growth factor 1
• insulin-like growth factor I
• insulin-like growth factor IA
• insulin-like growth factor IB
• Mechano growth factor
• MGF
• Somatomedin A
• Somatomedin C
• somatomedin-C

Background

Insulin-like growth factor I, also known as somatomedin C, is the dominant effector of growth hormone and is structurally homologous to proinsulin. Mouse IGF-I is synthesized as two precursor isoforms with alternate N- and C-terminal propeptides (1). These isoforms are differentially expressed by various tissues (1). The 7.6 kDa mature IGF-I is identical between isoforms and is generated by proteolytic removal of the N- and C-terminal regions. Mature mouse IGF-I shares 94% and 99% aa sequence identity with human and rat IGF-I, respectively (2), and exhibits cross-species activity. It shares 60% aa sequence identity with mature mouse IGF‑II. Circulating IGF-I is produced by hepatocytes, while local IGF-I is produced by many other tissues in which it has paracrine effects (1). IGF-I induces the proliferation, migration, and differentiation of a wide variety of cell types during development and postnatally (3). IGF-I regulates glucose and fatty acid metabolism, steroid hormone activity, and cartilage and bone metabolism (4-7). It plays an important role in muscle regeneration and tumor progression (1, 8). IGF-I binds IGF-I R, IGF-II R, and the insulin receptor, although its effects are mediated primarily by IGF-I R (9). IGF-I association with IGF binding proteins increases its plasma half-life and modulates its interactions with receptors (10).

1. Philippou, A. et al. (2007) In Vivo 21:45.
2. Bell, G.I. et al. (1986) Nucleic Acids Res. 14:7873.
3. Guvakova, M.A. (2007) Int. J. Biochem. Cell Biol. 39:890.
4. Clemmons, D.R. (2006) Curr. Opin. Pharmacol. 6:620.
5. Bluher, S. et al. (2005) Best Pract. Res. Clin. Endocrinol. Metab. 19:577.
6. Garcia-Segura, L.M. et al. (2006) Neuroendocrinology 84:275.
7. Malemud, C.J. (2007) Clin. Chim. Acta 375:10.
8. Samani, A.A. et al. (2007) Endocrine Rev. 28:20.
9. LeRoith, D. and S. Yakar (2007) Nat. Clin. Pract. Endocrinol. Metab. 3:302.
10. Denley, A. et al. (2005) Cytokine Growth Factor Rev. 16:421.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for IGF-I/IGF-1 Antibody (BAF791)(6)

Publications using BAF791

• PHIL-DONG MOON, MIN-HO KIM, HYUN-A OH, SUN-YOUNG NAM, NA-RA HAN, HYUN-JA JEONG et al. Cysteine induces longitudinal bone growth in mice by upregulating IGF-I International Journal of Molecular Medicine 8/1/2015 [PMID: 26101100]
• Fletcher L, Isgor E, Sprague S, Williams L, Alajajian B, Jimenez D, Digicaylioglu M Spatial distribution of insulin-like growth factor binding protein-2 following hypoxic-ischemic injury. BMC Neurosci, 2013-12-21;14(0):158. 2013-12-21 [PMID: 24359611] (ELISA Development (Detection), Mouse)
• Mehta HH, Gao Q, Galet C IGFBP-3 is a metastasis suppression gene in prostate cancer. Cancer Res., 2011-06-22;71(15):5154-63. 2011-06-22 [PMID: 21697285] (ELISA Development, Mouse)
• Yamada PM, Mehta HH, Hwang D Evidence of a role for insulin-like growth factor binding protein (IGFBP)-3 in metabolic regulation. Endocrinology, 2010-10-06;151(12):5741-50. 2010-10-06 [PMID: 20926583] (ELISA Development, Mouse)
• Wang N, Fallavollita L, Nguyen L, Burnier J, Rafei M, Galipeau J, Yakar S, Brodt P Autologous bone marrow stromal cells genetically engineered to secrete an igf-I receptor decoy prevent the growth of liver metastases. Mol. Ther., 2009-04-14;17(7):1241-9. 2009-04-14 [PMID: 19367255] (ELISA Development, Mouse)
• Raina K, Blouin MJ, Singh RP, Majeed N, Deep G, Varghese L, Glode LM, Greenberg NM, Hwang D, Cohen P, Pollak MN, Agarwal R Dietary feeding of silibinin inhibits prostate tumor growth and progression in transgenic adenocarcinoma of the mouse prostate model. Cancer Res., 2007-11-15;67(22):11083-91. 2007-11-15 [PMID: 18006855] (ELISA Development, Mouse)

Bioinformatics

• Gene Symbol: IGF1
• Uniprot:
  • Q8CAR0()